Twist Bioscience Corp. (TWST) shares surged 5.16% during intraday trading on Monday, as investors reacted positively to the company's fiscal third-quarter 2026 earnings release, which delivered a top-line beat, raised full-year guidance, and a clear path to adjusted EBITDA breakeven.

The company reported Q3 FY26 revenue of $118.4 million, up 23% year-over-year and comfortably above the FactSet consensus estimate of $114.5 million. Gross margin improved to 52.8%, while the adjusted EBITDA loss narrowed to $11.3 million. Management also raised its full-year fiscal 2026 revenue guidance to a range of $456 million to $457 million, up from the prior $442 million to $447 million, and projected fourth-quarter revenue of approximately $123 million to $124 million, well ahead of the $117.4 million consensus.

Adding to the bullish sentiment, Twist Bioscience said it expects to achieve adjusted EBITDA breakeven in the fiscal fourth quarter and sees full-year gross margins above 52%. The combination of accelerating revenue growth, margin expansion, and a near-term profitability milestone fueled the sharp intraday rally.